PMID- 33548318 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1879-0003 (Electronic) IS - 0141-8130 (Linking) VI - 175 DP - 2021 Apr 1 TI - Cloning and characterization of steroid 5beta-reductase from the venom gland of Bufo bufo gargarizans. PG - 67-78 LID - S0141-8130(21)00259-2 [pii] LID - 10.1016/j.ijbiomac.2021.01.211 [doi] AB - Bufadienolides are the main active ingredients of Venenum Bufonis, which is a widely used traditional Chinese medicine secreted from parotoid gland and skin glands of Bufo bufo gargarizans. According to the transcriptome analysis, "cholesterol-bile acid-bufadienolidies pathway" was proposed as animal-derived bufadienolides biosynthesis pathway by us previously. In this pathway 3beta-hydroxysteroid dehydrogenase (3betaHSD) and steroid 5beta-reductase (SRD5beta) might be the key enzymes to convert the A/B ring to cis-configuration. Therefore, as the second report of our group, here we report the cloning of the full length of SRD5beta cDNA of B. bufo gargarizans (Bbg-SRD5beta) from the parotoid gland of B. bufo gargarizans for the first time, and site-directed mutagenesis was used to explored the character of Bbg-SRD5beta. Bbg-SRD5beta had an open reading frame of 981 bp and encoded 326 amino acids residues. The expression conditions of the recombinant Bbg-SRD5beta in E. coli BL21 (DE3) harbored with pCold-Bbg-SRD5beta was optimized as induction for 10 h at 15 degrees C with 0.1 mM IPTG. With NADPH as a cofactor, Bbg-SRD5beta can reduce the Delta(4,5) double bonds of progesterone to generate dihydroprogesterone owithout substrate inhibition effect. The catalytic rate of mutant type Bbg-SRD5beta-Y132G was 1.8 times higher than that of wild type Bbg-SRD5beta. Although Bbg-SRD5beta was almost unable to reduce the progesterone to dihydroprogesterone after mutation of V309, the affinity of enzyme with NADPH changed significantly. Bbg-SRD5beta is the key enzymes to convert the A/B ring of steroid to cis-configuration, and V309 is a key site affecting the binding affinity of enzyme with NADPH, and the mutation of Y132 can adjust the catalytic rate of Bbg-SRD5beta. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Zhang, Yanan AU - Zhang Y AD - School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China. FAU - Li, Xue AU - Li X AD - School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China. FAU - Xu, Di AU - Xu D AD - School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China. FAU - Wu, Mengyun AU - Wu M AD - School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China. FAU - Dai, Yinghui AU - Dai Y AD - School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China. FAU - Xia, Mingyu AU - Xia M AD - School of Life Science and Biological Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: xmywd@vip.sina.com. FAU - Wang, Dong AU - Wang D AD - School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China. Electronic address: dongwang@syphu.edu.cn. LA - eng PT - Journal Article DEP - 20210203 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (Amphibian Venoms) RN - 0 (Bufanolides) RN - 0 (DNA, Complementary) RN - 0 (Steroids) RN - EC 1.- (Oxidoreductases) RN - EC 1.3.99.6 (3-oxo-5 beta-steroid delta 4-dehydrogenase) SB - IM MH - Amino Acid Sequence MH - Amphibian Venoms/*chemistry/metabolism MH - Animals MH - Bufanolides/chemistry/metabolism MH - Bufo bufo/*metabolism MH - Bufonidae/metabolism MH - Cloning, Molecular/methods MH - DNA, Complementary/metabolism MH - Open Reading Frames MH - Oxidoreductases/genetics/*isolation & purification/metabolism MH - Steroids/metabolism OTO - NOTNLM OT - Bufo bufo gargarizans OT - Mutation OT - Steroid 5beta-reductase OT - cis-configuration COIS- Declaration of competing interest The authors declare no conflict of interest. The founding sponsors had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/02/07 06:00 MHDA- 2021/07/23 06:00 CRDT- 2021/02/06 20:09 PHST- 2020/08/28 00:00 [received] PHST- 2021/01/29 00:00 [revised] PHST- 2021/01/30 00:00 [accepted] PHST- 2021/02/07 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2021/02/06 20:09 [entrez] AID - S0141-8130(21)00259-2 [pii] AID - 10.1016/j.ijbiomac.2021.01.211 [doi] PST - ppublish SO - Int J Biol Macromol. 2021 Apr 1;175:67-78. doi: 10.1016/j.ijbiomac.2021.01.211. Epub 2021 Feb 3.